FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2769474447> ?p ?o ?g. }

• W2769474447 endingPage "S1301" @default.
• W2769474447 startingPage "S1300" @default.
• W2769474447 abstract "Effective options are limited for patients with non-small cell lung cancer (NSCLC) with progressive disease after first-line chemotherapy. In these patients, immune checkpoint modulators have recently proven to be successful targets, being nivolumab the first immune checkpoint inhibitor approved for NSCLC. In contrast to conventional chemotherapy, these agents appear to have potential for effecting durable responses and possibly long-term survival. Immune checkpoint inhibitors generate atypical types of tumour responses and have a specific toxicity profile which is challenging current practices. Objective: To investigate outcomes and adverse effects in patients treated with nivolumab. Stage IV NSCLC patients treated with nivolumab at our centre between 30th September 2015 and 30th June 2016 were retrospectively analysed. We describe clinical features, toxicity and outcomes in these patients. Fifteen patients were included [mean age 62±8 years; mainly male (n=12)]. Almost all patients had a history of tobacco smoking (n=12; mean pack/year45). The observed histological type were adenocarcinoma (n=10) and squamous cell carcinoma (n=5). All patients received prior systemic therapy, mainly platinum based regimens. At time of the initiation of nivolumab most patients had an ECOG performance-status score of 1 (n=12) and stage IV cancer (n=10). Only one patient received subsequent cancer therapy and the remaining alive patients at time of the study was still under nivolumab treatment. Mean duration of treatment was 3.5months (median of 4 cycles). The median survival since the beginning of nivolumab was 2.3months (min 7 days; max 8.7 months). Treatment-related adverse events of grade 1 or 2 were reported in 20% of the patients: thyroid hormone alterations were present in 3 patients and 2 needed thyroid hormone replacement; 1 patient presented immune related eczema and another suspected myocarditis. Two patients suspended nivolumab temporarily and two patients died. Besides the efficacy profile of immune targeted agents it is important to be aware of possible immune-related adverse events. These toxicities remain largely unknown and will be more frequent in routine practice as the number of patients treated with nivolumab increases. Although severe adverse effects remain rare, they can become life-threatening if not anticipated and managed appropriately. Ongoing evaluation is needed to define the most appropriate timing and patient population that will benefit from therapy with an immune checkpoint inhibitors and to learn how to deal with its adverse effects." @default.
• W2769474447 created "2017-12-04" @default.
• W2769474447 creator A5001863309 @default.
• W2769474447 creator A5026876336 @default.
• W2769474447 creator A5030755226 @default.
• W2769474447 creator A5087944647 @default.
• W2769474447 date "2017-01-01" @default.
• W2769474447 modified "2023-09-26" @default.
• W2769474447 title "P3.02c-043 Immunotherapy in Non-Small Cell Lung Cancer: A New Approach and a New Challenge" @default.
• W2769474447 doi "https://doi.org/10.1016/j.jtho.2016.11.1838" @default.
• W2769474447 hasPublicationYear "2017" @default.
• W2769474447 type Work @default.
• W2769474447 sameAs 2769474447 @default.
• W2769474447 citedByCount "2" @default.
• W2769474447 countsByYear W27694744472017 @default.
• W2769474447 countsByYear W27694744472018 @default.
• W2769474447 crossrefType "journal-article" @default.
• W2769474447 hasAuthorship W2769474447A5001863309 @default.
• W2769474447 hasAuthorship W2769474447A5026876336 @default.
• W2769474447 hasAuthorship W2769474447A5030755226 @default.
• W2769474447 hasAuthorship W2769474447A5087944647 @default.
• W2769474447 hasBestOaLocation W27694744471 @default.
• W2769474447 hasConcept C121608353 @default.
• W2769474447 hasConcept C126322002 @default.
• W2769474447 hasConcept C143998085 @default.
• W2769474447 hasConcept C197934379 @default.
• W2769474447 hasConcept C2776256026 @default.
• W2769474447 hasConcept C2776694085 @default.
• W2769474447 hasConcept C2777701055 @default.
• W2769474447 hasConcept C2778822529 @default.
• W2769474447 hasConcept C2780030458 @default.
• W2769474447 hasConcept C2781182431 @default.
• W2769474447 hasConcept C71924100 @default.
• W2769474447 hasConceptScore W2769474447C121608353 @default.
• W2769474447 hasConceptScore W2769474447C126322002 @default.
• W2769474447 hasConceptScore W2769474447C143998085 @default.
• W2769474447 hasConceptScore W2769474447C197934379 @default.
• W2769474447 hasConceptScore W2769474447C2776256026 @default.
• W2769474447 hasConceptScore W2769474447C2776694085 @default.
• W2769474447 hasConceptScore W2769474447C2777701055 @default.
• W2769474447 hasConceptScore W2769474447C2778822529 @default.
• W2769474447 hasConceptScore W2769474447C2780030458 @default.
• W2769474447 hasConceptScore W2769474447C2781182431 @default.
• W2769474447 hasConceptScore W2769474447C71924100 @default.
• W2769474447 hasIssue "1" @default.
• W2769474447 hasLocation W27694744471 @default.
• W2769474447 hasOpenAccess W2769474447 @default.
• W2769474447 hasPrimaryLocation W27694744471 @default.
• W2769474447 hasRelatedWork W2141197908 @default.
• W2769474447 hasRelatedWork W2358156577 @default.
• W2769474447 hasRelatedWork W2743577629 @default.
• W2769474447 hasRelatedWork W2972926806 @default.
• W2769474447 hasRelatedWork W3029010559 @default.
• W2769474447 hasRelatedWork W3097428643 @default.
• W2769474447 hasRelatedWork W3137670083 @default.
• W2769474447 hasRelatedWork W3171615116 @default.
• W2769474447 hasRelatedWork W3175383630 @default.
• W2769474447 hasRelatedWork W3215044659 @default.
• W2769474447 hasVolume "12" @default.
• W2769474447 isParatext "false" @default.
• W2769474447 isRetracted "false" @default.
• W2769474447 magId "2769474447" @default.
• W2769474447 workType "article" @default.